GILD vs MRNA stock comparison
Gilead Sciences vs. Moderna · data as of November 13, 2026
Gilead Sciences (GILD) has a market value of about $208.5B, Moderna (MRNA) about $90.4B. Over their latest twelve months Gilead Sciences had revenue of $31.0B and Moderna $2.5B.
On our five checks Gilead Sciences scores higher: 2.8 out of 5 (average) against 1.0 (weak).
By area, the stronger company is Gilead Sciences on value; Gilead Sciences on future growth; Gilead Sciences on track record; Gilead Sciences on financial health; Gilead Sciences on shareholder returns.
Gilead Sciences leads on 15 of the compared lines and Moderna on 3.
Side by side
| GILD | MRNA | |
|---|---|---|
| Size and price | ||
| Market cap | $208.5B | $90.4B |
| Share price | $168.08 | $223.37 |
| Score | ||
| Overall score (of 5) | 2.8 | 1.0 |
| Value | 1 | 0 |
| Future growth | 2 | 1 |
| Track record | 4 | 1 |
| Financial health | 3 | 2 |
| Shareholder returns | 4 | 1 |
| Valuation | ||
| P/E (TTM) | — | — |
| Forward P/E | 20.3 | — |
| Price / free cash flow | 15.1 | — |
| Price / sales | 6.7 | 35.8 |
| EV / EBITDA | 559.5 | — |
| PEG | — | — |
| DCF value vs. price | −35% | — |
| Business | ||
| Revenue | $31.0B | $2.5B |
| Net income | -$3.9B | -$2.8B |
| Free cash flow | $13.8B | -$2.0B |
| Net margin | -12.5% | -110.5% |
| Gross margin (5-yr avg.) | 77.6% | 59.9% |
| ROIC (5-yr avg.) | 12.2% | 9.4% |
| Growth | ||
| Revenue growth (1 yr) | 2.4% | -39.9% |
| Revenue growth (5 yrs, per year) | 3.6% | 19.3% |
| EPS growth (5 yrs, per year) | 132.4% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$19.8B | $3.9B |
| Dividend yield | 1.95% | None |
| Shareholder yield | 2.9% | 0.0% |
| Analysts | ||
| Upside to average target | +4% | −29% |
| Consensus rating | Buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: GILD TTM to September 30, 2026, MRNA TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Gilead Sciences or Moderna?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Gilead Sciences scores 2.8 out of 5 and Moderna 1.0; the table shows where each one is stronger.
Which grows faster, Gilead Sciences or Moderna?
Over five years Moderna grew revenue about 19.3% a year and Gilead Sciences about 3.6% a year.
Which pays a higher dividend?
Gilead Sciences yields 1.95% and Moderna nothing (no dividend).
Full Gilead Sciences analysis → Full Moderna analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.